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Abstract
Extracorporeal  membrane  oxygenation  (ECMO)  is  a  supportive  therapy,  which
provides cardiopulmonary and end-organ support in critically ill patients when other
measures fail. These patients receive large amounts of fluid for volume resuscitation,
blood products and caloric intake, which results in fluid overload and which in turn is
associated with impairment of oxygen transport and increased incidence of multiple
organ failure especially heart, lungs and brain. It is common to see a decrease in urine
output during ECMO that may be associated with acute renal failure. The acute renal
failure is a manifestation of multiple organ system failure due to acute decompensat‐
ed  heart  failure,  sepsis,  hemolysis,  use  of  vasopressors/inotropes,  nephrotoxic
medications,  and  activation  of  complement  system  during  ECMO  support.  It  is
associated with poor prognosis and higher mortality in ECMO patients. Continuous
renal replacement therapy (CRRT) in patients on ECMO provides an efficient and
potentially beneficial method of fluid overload and acute kidney injury management.
In  addition,  recent  data  suggest  that  the  use  of  CRRT may remove inflammatory
cytokine released as a result of circulation of blood across synthetic surfaces during
ECMO. The two most common methods to provide CRRT are through the use of an
inline hemofilter or through a traditional CRRT device connected to the extracorpor‐
eal circuit. The primary objective of this chapter is to discuss current state and role of
renal replacement therapy in patients on ECMO and address the controversies and
challenges about its application.
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1. Introduction
Extracorporeal membrane oxygenation (ECMO) is a modality of treatment used in the inten‐
sive care unit (ICU) to improve gas exchange in patients with life-threatening respiratory failure
and when conventional therapeutic methods fail to sustain sufficient oxygenation and/or the
removal of carbon dioxide. Renal replacement therapy (RRT) is added to the ECMO for the
treatment of acid-base as well as electrolyte imbalance and fluid overload. This chapter is trying
to discuss the current state and role of renal replacement therapy in patients on ECMO and
address the controversies and challenges about its application.
2. Continuous renal replacement therapy
Continuous renal replacement therapy (CRRT) is the mode of therapy adopted in patients with
hemodynamic instability in whom intermittent hemodialysis cannot control volume or
metabolic derangements. The concept of CRRT was introduced in 1980 and was used mainly
for management of critically ill patients with acute kidney injury (AKI). The better hemody‐
namic tolerance seen in CRRT is due to slower solute clearance and removal of fluid per unit
of time. CRRT works on the principle of convection and diffusion. In regular hemodialysis,
diffusion is the modality of solute movement and ultrafiltration is added to the process for the
purpose of fluid removal. One of the major disadvantages of conventional hemodialysis is that
it is done only for limited amount of time, and hence it is difficult to achieve adequate fluid
removal in patients who have hemodynamic instability. Moreover, critically ill patients receive
large amounts of fluid and in the presence of reduced renal function keeping the fluid balance
is a challenge. Hence, CRRT treatment is appropriate for patients with hemodynamic insta‐
bility, fluid overload, catabolism, or sepsis with acute kidney injury (AKI) [1].
The usual CRRT circuit involves a double lumen catheter, tubing to carry blood from patient’s
body through the catheter to the CRRT machine, CRRT machine and return tubing which sends
the blood back to the patient's body. There are three different modes of doing CRRT: contin‐
uous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD),
and continuous venovenous hemodiafiltration (CVVHDF). CVVHD works on the principle of
diffusion and hence it is inefficient in terms of removal of large molecular weight substances.
On the other hand, CVVH works on the principle of convection, which is the movement of
water along with electrolytes, and CVVHDF employs both diffusion and convection. Convec‐
tion is dependent on the pressure and pore size of the membrane. Perfusion pressure generated
by a peristaltic pump drives the ultrafiltration of plasma across a biosynthetic hemofiltration
membrane. In this process, a high ultrafiltration rate is required to achieve convective clearance
and hence replacement fluid must be added to the extracorporeal circuit to restore fluid volume
and electrolytes [1].
The solution bags used for doing CRRT contains glucose and electrolytes (including sodium,
potassium, calcium, and magnesium) in concentrations that are in the physiologic range. The
dose of CRRT is decided based on effluent dose. It is defined as the flow of effluent in ml/kg/
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hr. Based on clinical studies, the recommended effluent dose is 20–25 ml/kg/hr. But at the same
time, solute clearance will be affected by clotting and protein deposition on the hemofilter
membrane. Anticoagulants are also added to the circuit for the sake of keeping the filter patent
for a longer period and usual anticoagulants used include citrate and heparin. The usual blood
flow rates on CRRT circuit range 150–250 cc/min.
Although CVVHDF is preferred over CVVH in most institutions, there is no one modality,
which is shown to be superior over the other. There might be a theoretical advantage for CVVH
and CVVHD in terms of removing larger molecules like cytokines in septic patients. But at the
same time, relevant clinical studies have not shown any benefit in terms of improvement in
plasma concentration of cytokines or outcome.
3. Technical aspects of combining ECMO and CRRT
There are a number of ways CRRT can be initiated in a patient undergoing treatment with
ECMO. The most common technique is using separate vascular access and circuit for CRRT
and ECMO. This technique ensures that both systems do not interfere with each other’s
hemodynamics. One of the disadvantages with this connection is the introduction of a large
cannula while the patient is on anticoagulation which increases the risk of bleeding compli‐
cations at the time of insertion. Additionally in some cases, multiple vascular access sites might
be required for doing ECMO which will limit the number of access sites available for estab‐
lishing CRRT circuit.
Another method is by introducing the CRRT machine or a hemofilter into the ECMO circuit
otherwise called as inline technique. Here blood for the CRRT circuit is accessed from and
returned to ECMO circuit. Inlet to the CRRT circuit can be before or after the oxygenator or
centrifugal pump. Similarly, venous return from CRRT circuit is connected to ECMO circuit
before or after the oxygenator or centrifugal pump. In ECMO circuits, using roller pump, a
similar setting can be established. Inline hemofilter is used in conditions where the goal is only
to remove the fluid and not solutes. The different inline ECMO/CRRT/hemofilter connections
are depicted in Figures 1–5. Advantages of incorporating the CRRT circuit into the ECMO
circuit include (1) cost effectiveness, (2) easy to set up the circuit, (3) use of low blood volume,
(4) ease of operability, (5) less resource intensive, (6) avoid additional access placement and
ensuing complications especially in the background of anticoagulation use, and (7) the
oxygenator in the ECMO circuit can work as an air bubble and blood clot trap for both the
ECMO and CRRT circuit (provided both inlet and outlet lines are connected to the ECMO
circuit before the oxygenator or to the oxygenator). One of the major disadvantages of
incorporating the CRRT circuit into the ECMO line is the interference of blood flow in the
CRRT as well as the ECMO circuit. If the CRRT machine’s venous (outlet) line is connected to
the ECMO circuit before the centrifuge pump, purified blood from the CRRT returns into the
negative pressure part of the ECMO circuit. This generates low return pressure alarm in the
CRRT machine which may subsequently shut down the machine. The connection of arterial
line post pump can trigger too high pressure on the arterial access side of the CRRT generating
alarms inside the CRRT machine. Conversely, connections with arterial line pre-pump and
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venous line post-pump can trigger low-pressure arterial (access) alarms and high-pressure
return (venous) alarms in the CRRT circuit, respectively. These can interfere with pressure
monitoring within the CRRT filter reducing the lifespan of the filter. Moreover, the drastic
difference in flow and pressure will increase shear stress, activate the clotting cascade and
release noxious cytokines. This, in turn, can predispose to the potential life-threatening
hemolysis, disseminated intravascular coagulation and enhanced systemic inflammation. The
hemolysis through the medium of hemoglobinuria can precipitate renal injury [2, 3].
Figure 1. ECMO-CRRT connection with inlet of the CRRT circuit connected to the inlet line of ECMO circuit precentri‐
fugal pump and outlet of the CRRT circuit to the ECMO circuit postcentrifugal pump.
Figure 2. ECMO-CRRT connection with inlet of the CRRT circuit connected to ECMO circuit postcentrifugal pump and
outlet of the CRRT circuit to the ECMO circuit precentrifugal pump.
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Figure 3. ECMO-CRRT connection with inlet and outlet of the CRRT circuit connected to ECMO oxygenator.
Figure 4. ECMO-CRRT connection with inlet of the CRRT circuit connected to ECMO circuit postoxygenator and out‐
let of the CRRT circuit to the ECMO circuit precentrifugal pump.
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Figure 5. ECMO-hemofilter connection in an ECMO machine with centrifugal pump. The inlet of the hemofilter circuit
is connected to ECMO circuit postcentrifugal pump and the outlet of the hemofilter circuit is connected to the ECMO
circuit precentrifugal pump.
The flow of blood from and into the ECMO circuit can interfere with blood flow in the ECMO
circuit. The support for a patient with severe hypoxemia often requires high blood flow with
a pump speed of above 3000 rpm and the flow of blood into CRRT circuit may generate very
low pressure particularly when the inflow to the ECMO circuit is limited. This may have
clinical consequences in patients with severe hypoxemia where even small fluctuations in the
ECMO flow can lead to significant drop in the arterial blood oxygenation [2, 3].
4. Indications and benefits of combined ECMO-CRRT treatment
Classic indications for initiation of renal replacement therapy in patients on ECMO include
uremia, acidosis, electrolyte abnormalities, and fluid overload. The most frequently reported
indications were fluid overload (43%), prevention of fluid overload (16%), AKI (35%), elec‐
trolyte disturbances (4%), and other (2%). Combined use of ECMO and CRRT has many
benefits. ECMO by itself is an effective means of providing cardiorespiratory support for these
patients. Similarly, provision of ECMO support may prevent the myocardial damage that can
be caused by inotropic agents or hypoxia and promote hasty recovery of myocardial function.
Both these factors can improve oxygenation and perfusion of organs including the kidneys
which in turn may promote early recovery of renal failure. Correction of hypoxia using the
ECMO machine can result in the reduction of lactic acidosis. The addition of CRRT (with
bicarbonate-based solutions) efficiently manages severe lactic acidosis avoiding fluid overload
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and hypocalcemia in hemodynamically unstable patients. Hence combining ECMO with
CRRT might result in rapid reversal of the metabolic sequelae of lactic acidosis [4–6].
Another major advantage of combining CRRT with ECMO is the establishment of favorable
volume status. Improvement in fluid overload or improving fluid balance has been found to
be associated with improved lung function, faster recovery of left ventricular function, better
diastolic compliance, better contractility and less myocardial edema and time to weaning off
ECMO and ventilator support. In addition to the above-mentioned advantages, initiation of
renal replacement therapy (RRT) also allows for the administration of adequate nutrition,
medications, and blood products, while avoiding further fluid accumulation. It can correct
azotemia, electrolyte imbalance and decrease levels of inflammatory cytokines as well as
systemic inflammatory response syndrome induced by ECMO. The latter might be beneficial
in terms of decreasing ECMO-induced renal injury [4–6].
5. Timing of initiation of CRRT in ECMO patients
The timing of initiation of CRRT on ECMO is not well defined. Clinical studies have shown a
beneficial role of early initiation of CRRT and better outcomes in patients on ECMO. The
benefits of early initiation of CRRT in these studies were mostly related to maintenance of fluid
balance. Excessive fluid has been found to be associated with prolonged ECMO duration,
mechanical ventilation, longer length of stay in the ICU, and mortality. CRRT is an important
tool for managing fluid overload in these patients since it enables goal-directed maintenance
of fluid balance. Hence, early initiation of CRRT before the onset of fluid overload should be
considered in patients on ECMO. Blijdorp et al. observed that initiating preemptive CRRT
during ECMO in neonatal patients improved outcomes by decreasing time on ECMO due to
improved fluid management [6, 7]. It has also been shown that odds ratio for death was higher
when CRRT was started later and longer it was performed.
6. Complications of ECMO and CRRT
Complications of CRRT are related to placement of vascular access, cardiac arrhythmias,
electrolyte disturbances, nutrient losses, hypothermia, and bleeding complications from
anticoagulation. Common vascular access-related complications include arterial puncture,
hematoma, hemothorax, pneumothorax, formation of arteriovenous fistulas, aneurysms,
thrombus formation, pericardial tamponade, and retroperitoneal hemorrhage. Electrolyte
imbalances commonly encountered include hypokalemia and hypophosphatemia, which may
lead to complications such as hemolysis and rhabdomyolysis. In unstable patients with
multiple organ failures and fluid overload, although ECMO alone can improve hemodynamic
stability by increasing cardiac output via an ECMO pump (in venoarterial ECMO) and
improved myocardial oxygenation, the presence of fluid overload can nullify these advantag‐
es. Hence, maintenance of fluid balance is very essential in the treatment of critically ill patients
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supported with ECMO and CRRT. Experimental and observational data have shown that
ECMO itself can have hemodynamic consequences and can interfere with the accurate
assessment of volume status. Traditional markers of volume assessment like CVP can be
unreliable in these patients. Larsson et al. in his experiments in swine model showed that
venoarterial ECMO can decrease systemic venous pressure while maintaining systemic
perfusion leading to diminution of central venous pressure measurement [8]. Additionally,
volume assessment can be made difficult by the myocardial dysfunction secondary to use of
ECMO. Numerous mechanisms have been proposed for the pathogenesis of this phenomenon
including low ionized calcium at the onset of cardiac bypass, effect of reactive oxygen species,
toxic substances related to the ECMO circuit, various cytokines involved in inflammation
during ECMO on the myocardium, retrograde nonpulsatile blood flow, particularly, in the
background of underlying left ventricular dysfunction, coronary hypoxia due to higher
oxyhemoglobin saturation in the lower extremities compared to upper body (exclusively seen
with use of femoral arterial catheter placement in a VA ECMO configuration), and increase in
left ventricular afterload. ECMO can additionally result in cardiac stunning as reported by
Martin et al. [9]. Pyles et al. [10] in their experiment on Dorset lambs found that initiation of
ECMO is associated with decreased hemodynamic and echocardiographic measures of LV
function despite accounting for changes in afterload.
The incidence of AKI in patients on ECMO is estimated to be up to 70%. AKI with the need
for renal replacement therapy (RRT) occurs in 50% of patients on ECMO and it is one of the
most frequent additional organ failures in this patient population. ECMO initiation by itself
can lead to acute kidney injury; the mechanisms include ischemia/reperfusion injury from
rapid hemodynamic fluctuation in renal blood flow secondary to adjustments in vasopressors
or inotropes, pigment nephropathy due to hemoglobinuria resulting from hemolysis secon‐
dary to exposure of blood to artificial surfaces, nonpulsatile retrograde renal perfusion,
activation of complement system, and accumulation of cytokines. Development of renal failure
is a reflection of progression to multisystem organ failure. Moreover, it can predispose to the
accumulation of fluid and subsequent volume overload worsening heart and lung disease.
7. Renal recovery and combined ECMO-CRRT
Renal recovery outcome data are limited in patients who have received ECMO and CRRT.
Paden et al. [11] in his study of 154 patients on ECMO and CRRT showed that renal recovery
was seen in 96% of the patients who survived. Similarly, Meyer et al. [12] in a series of neonatal
and pediatric survivors renal recovery was seen in 14/15 (93%) patients. In the study by
Thajudeen et al., the renal recovery was found in all patients who survived. In his study, a key
observation was that all those patients who had renal recovery were on VA ECMO and they
hypothesized that the increased oxygen supply to renal vessels due to its close proximity to
heart in the cases of VA ECMO might have played a role in the renal recovery [13]. All these
studies show a favorable renal outcome in patients who survive.
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8. Mortality in patients on combined ECMO and CRRT
Clinical studies have shown the association between ECMO, CRRT, and high mortality. In a
retrospective study of 200 patients who underwent ECMO 60% (120/200) required renal
replacement therapy (RRT) for AKI and the survival of patients requiring RRT was only 17%.
Wu et al. [14] made a similar observation where the need for RRT was found to be an inde‐
pendent risk factor for mortality. Although survival in ECMO patients has improved tremen‐
dously over the years, the addition of CRRT portends a worse prognosis eliminating this
advantage. Severity of illness has been suggested as a cause of high mortality in these patients.
It is also speculated that in the presence of multiple organ dysfunction syndromes (MODS),
the presence of AKI itself rather than the requirement for CRRT is the independent risk factor
for mortality in critically ill patients undergoing ECMO.
There are data supporting an association between delayed start of CRRT and mortality.
Kielstein et al. [15] observed that the 90-day survival of patients on ECMO needing CRRT was
only 17%; however, at the same time they found that the cohort of patients who had delayed
the start of CRRT had higher mortality. Randomized controlled studies comparing early vs.
late initiation of CRRT before and after the occurrence of the fluid overload in patients on
ECMO would be needed to further address this issue.
9. Antibiotic dosing in CRRT and ECMO
While ECMO and CRRT are important modes of therapy that can sustain life, little is known
about the independent effects of ECMO and CRRT on antibiotic pharmacokinetics. Clear data
on the dosing of medications are lacking at this point. Patients on extracorporeal circuit usually
will have increased volume of distribution and variable clearance. Clinical studies have shown
significant alterations in the pharmacokinetics which can result in suboptimal dosing of
medications (both under- and overdosing). Inadequate or underdoing of antibiotics can lead
to inadequate treatment of sepsis and subsequent increase in morbidity and mortality.
Similarly, too high dosing can lead to systemic toxicity. This is significant in these patients who
already have high infection-related mortality. Guidelines for dosing of medications should
take into consideration the mode of RRT, dose of RRT delivered, blood flow rate, filter material,
and surface area of the filter [16–18].
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